Firm Advises Allergan in $66 Billion Merger with Actavis

Combination creates a top 10 global pharmaceutical company.

November 17, 2014

Actavis plc and Allergan, Inc. have announced a definitive agreement under which Actavis will acquire Allergan in a cash and stock transaction valued at approximately $66 billion. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. The transaction, which has been unanimously approved by the Boards of Directors of Actavis and Allergan, is subject to the approval of the shareholders of both companies, as well as customary antitrust clearance in the US, the EU and certain other jurisdictions, and is anticipated to close in the second quarter of 2015. 

Latham & Watkins LLP represents Allergan in the transaction with a corporate team led by partners Cary Hyden, Paul Tosetti and Michael Treska, with associates Daniel Rees and Aneta Ferguson. Hyden, Treska, Rees and Ferguson are based in Orange County, CA; and Tosetti in Los Angeles. Advice has also been provided on antitrust matters by partners Karen Silverman and Joshua Holian in San Francisco, with counsel Sydney Smith in Washington, D.C.; on benefits and compensation matters by partner Jim Barrall in Los Angeles and associate Maj Vaseghi in Silicon Valley; on environmental matters by partner Christopher Norton in Orange County; on finance matters by partner Glen Collyer in Los Angeles; on intellectual property matters by counsel David Kuiper in Orange County; on regulatory matters by partner John Manthei in Washington, D.C. with counsels Betty Pang in San Francisco and Rebecca Brandt in Houston; and on tax matters by partner Laurence Stein and associate Eric Song in Los Angeles.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.